JP4638098B2 - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP4638098B2
JP4638098B2 JP2001502830A JP2001502830A JP4638098B2 JP 4638098 B2 JP4638098 B2 JP 4638098B2 JP 2001502830 A JP2001502830 A JP 2001502830A JP 2001502830 A JP2001502830 A JP 2001502830A JP 4638098 B2 JP4638098 B2 JP 4638098B2
Authority
JP
Japan
Prior art keywords
tumor
agent
tumor growth
tumors
dmxaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001502830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501460A5 (https=
JP2003501460A (ja
Inventor
クリッサンセン，ジェフリー・ウェイン
カンワル，ジャガット・ラケシュ
チン，ライ‐ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2003501460A publication Critical patent/JP2003501460A/ja
Publication of JP2003501460A5 publication Critical patent/JP2003501460A5/ja
Application granted granted Critical
Publication of JP4638098B2 publication Critical patent/JP4638098B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001502830A 1999-06-14 2000-06-14 癌治療 Expired - Fee Related JP4638098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ336259 1999-06-14
NZ33625999 1999-06-14
PCT/NZ2000/000098 WO2000076497A1 (en) 1999-06-14 2000-06-14 Cancer therapy

Publications (3)

Publication Number Publication Date
JP2003501460A JP2003501460A (ja) 2003-01-14
JP2003501460A5 JP2003501460A5 (https=) 2007-08-02
JP4638098B2 true JP4638098B2 (ja) 2011-02-23

Family

ID=19927331

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001502830A Expired - Fee Related JP4638098B2 (ja) 1999-06-14 2000-06-14 癌治療

Country Status (8)

Country Link
US (1) US20040086498A9 (https=)
EP (1) EP1189611B1 (https=)
JP (1) JP4638098B2 (https=)
AT (1) ATE324888T1 (https=)
AU (1) AU5717400A (https=)
DE (1) DE60027719T2 (https=)
ES (1) ES2265948T3 (https=)
WO (1) WO2000076497A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
US20070021392A1 (en) * 2000-03-31 2007-01-25 Davis Peter D Divided dose therapies with vascular damaging activity
ATE298240T1 (de) * 2000-03-31 2005-07-15 Angiogene Pharm Ltd Getrennte dosis therapien mit gefässschädigender aktivität
AU2001282717A1 (en) * 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
GB2384428A (en) * 2002-01-29 2003-07-30 Thromb X Nv Inhibitors of HIF
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
JP4546454B2 (ja) * 2003-01-28 2010-09-15 レクサーン・コーポレイション Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
EP1601325B1 (en) * 2003-01-31 2009-09-02 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
FR2835838B1 (fr) * 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
CA2463464A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
US20070218551A1 (en) * 2003-10-02 2007-09-20 Chuan-Yuan Li Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US7618947B2 (en) * 2004-08-25 2009-11-17 Isis Pharmaceuticals, Inc. Modulation of HIF-1 beta expression
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CA2620436A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
US9750819B2 (en) * 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
WO2016079899A1 (ja) * 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JP2672101B2 (ja) * 1986-12-23 1997-11-05 ディーエフシー ニュージーランド リミテッド キサンテノン−４−酢酸誘導体
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5075287A (en) * 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
JPH03116857A (ja) * 1989-09-29 1991-05-17 Mitsui Petrochem Ind Ltd 発光または受光装置
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
JPH0940690A (ja) * 1995-05-23 1997-02-10 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US5977077A (en) * 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5817684A (en) * 1996-12-13 1998-10-06 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
US5914340A (en) * 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
US5998454A (en) * 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
HUP9904672A2 (hu) * 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
DE19721211A1 (de) * 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
AU3822701A (en) * 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
AU2001282717A1 (en) * 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
US20040086498A9 (en) 2004-05-06
ATE324888T1 (de) 2006-06-15
EP1189611B1 (en) 2006-05-03
JP2003501460A (ja) 2003-01-14
ES2265948T3 (es) 2007-03-01
EP1189611A1 (en) 2002-03-27
DE60027719T2 (de) 2007-04-26
WO2000076497A1 (en) 2000-12-21
US20030003092A1 (en) 2003-01-02
EP1189611A4 (en) 2003-05-02
AU5717400A (en) 2001-01-02
DE60027719D1 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
JP4638098B2 (ja) 癌治療
Bartee et al. Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy
US20260049111A1 (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
Trojaniello et al. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy
US10350275B2 (en) Methods of cytotoxic gene therapy to treat tumors
US20130071403A1 (en) Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR20190112263A (ko) 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2017083441A1 (en) Modified immune cells and uses thereof
US20220226402A1 (en) Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
Ma et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy
Ollivier et al. Interaction between modern radiotherapy and immunotherapy for metastatic prostate cancer
EP1390075B1 (en) Chemotherapeutic induction of egr-1 promoter activity in gene therapy
O'Connor et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors
WO2018075447A1 (en) Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
RU2767997C2 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА
Gardner et al. The regulatory status adopted by lymph node dendritic cells and T cells during healthy aging is maintained during cancer and may contribute to reduced responses to immunotherapy
US20240042061A1 (en) Methods and compositions comprising tumor suppressor gene therapy for the inhibition of pathogens
US20190083556A1 (en) Analytical methods and arrays for use in the same
EP4514363A1 (en) Compositions and methods for preventing t cell exhaustion
WO2002094310A1 (en) Anti-angiogenic and immunotherapeutic compositions for cancer treatment
Lambert et al. Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on
HK40046148B (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
HK40046148A (en) Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101029

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101125

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees